ASCO GUIDELINES Bundle

Hepatocellular Carcinoma Pocket Guide - 2021

ASCO GUIDELINES App Bundle brought to you fcourtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1444713

Contents of this Issue

Navigation

Page 2 of 3

Treatment ➤ Recommendation 1.2: Where there are contraindications to atezolizumab and/or bevacizumab, tyrosine kinase inhibitors (TKIs) sorafenib or lenvatinib may be offered as first-line treatment of patients with advanced HCC, Child- Pugh class A, and ECOG PS 0-1 (Strong recommendation; EB-B-M). Qualifying statements: ▶ Treatment with recommended TKIs may be less effective for patients with more advanced liver cirrhosis. Careful patient selection is recommended. ▶ The choice of treatment with lenvatinib or sorafenib should be made through a discussion involving the physician and patient (and caregiver, where applicable) and should include factors such as medical history, viral etiolog y of liver disease, toxicities associated with treatment, cost, goals of treatment, patient preference, and expected treatment benefit. Factors affecting this choice, including response rates, are discussed further in the Clinical Interpretation. ▶ Several meta-analyses of RCTs have shown sorafenib to be more beneficial in patients with HCV, especially as compared with patients with HBV. In the REFLECT trial, there was a trend toward improvements across endpoints for lenvatinib over sorafenib in the HBV subgroup, though it was not significant. ▶ Patients with a high tumor burden, >50% liver involvement, or those with main portal vein invasion were excluded from the REFLECT trial of sorafenib versus lenvatinib. Second-Line Therapy ➤ Recommendation 2.1: Following first-line treatment with atezo + bev, second-line therapy with a TKI (ie, sorafenib, lenvatinib, cabozantinib, or regorafenib) may be recommended (Weak recommendation; IC-B-L). Qualifying statement: ▶ No data have been published on therapy options after first-line treatment with atezo + bev. It is the opinion of the Expert Panel that a TKI, preferably sorafenib or lenvatinib, may be offered. Cabozantinib or regorafenib are also reasonable options for second-line therapy following atezo + bev. ➤ Recommendation 2.2. Following first-line therapy with sorafenib or lenvatinib, second-line therapy with another TKI (cabozantinib or regorafenib), ramucirumab (AFP ≥400 ng/mL), or atezo + bev may be recommended for appropriate candidates. (Considerations regarding choice of therapy are included in the full text Guideline) (Weak recommendation; IC-B-L/M). Qualifying statement: ▶ It is likely that most patients being considered for atezo + bev in the second-line setting did not have access to this combination when they started first-line treatment. ➤ Recommendation 2.3: Following first-line therapy with sorafenib or lenvatinib, pembrolizumab or nivolumab are reasonable options that may be considered for appropriate candidates (Weak recommendation; IC-B-L). Qualifying statement: ▶ Immune checkpoint inhibitors pembrolizumab or nivolumab may be especially beneficial for patients who have contraindications to or cannot tolerate TKIs.

Articles in this issue

Archives of this issue

view archives of ASCO GUIDELINES Bundle - Hepatocellular Carcinoma Pocket Guide - 2021